BRIEF-IGM Biosciences Announces Fourth Quarter And Full Year 2023 Financial Results

Reuters03-08

March 7 (Reuters) - IGM Biosciences Inc :

* IGM BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* IGM BIOSCIENCES INC - CASH AND INVESTMENTS AS OF DECEMBER 31, 2023 WERE $337.7 MILLION

* IGM BIOSCIENCES INC - EXPECTS FULL YEAR 2024 GAAP OPERATING EXPENSES OF $210 MILLION TO $220 MILLION

* IGM BIOSCIENCES - SEES TO END 2024 WITH A BALANCE OF ABOUT $180 MILLION IN CASH AND INVESTMENTS

* IGM BIOSCIENCES - SEES CASH BALANCE TO ENABLE IT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q2 OF 2026

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2417203748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-08 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2417203748","market":"us","top_or_hot":-1,"title":"BRIEF-IGM Biosciences Announces Fourth Quarter And Full Year 2023 Financial Results","media":"Reuters","content":"<html><body><p>March 7 (Reuters) - <a href=\"https://laohu8.com/S/IGMS\">IGM Biosciences</a> Inc   :</p><p>   * IGM BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE</p><p>   * IGM BIOSCIENCES INC - CASH AND INVESTMENTS AS OF DECEMBER 31, 2023 WERE $337.7 MILLION</p><p>   * IGM BIOSCIENCES INC - EXPECTS FULL YEAR 2024 GAAP OPERATING EXPENSES OF $210 MILLION TO $220 MILLION</p><p>   * IGM BIOSCIENCES - SEES TO END 2024 WITH A BALANCE OF ABOUT $180 MILLION IN CASH AND INVESTMENTS</p><p>   * IGM BIOSCIENCES - SEES CASH BALANCE TO ENABLE IT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q2 OF 2026</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-IGM Biosciences Announces Fourth Quarter And Full Year 2023 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-IGM Biosciences Announces Fourth Quarter And Full Year 2023 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-08 05:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 7 (Reuters) - IGM Biosciences Inc   :   * IGM BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE   * IGM BIOSCIENCES INC - CASH AND ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2417203748","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2417203748","pubTimestamp":1709846041,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 7  - IGM Biosciences Inc   :   * IGM BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE   * IGM BIOSCIENCES INC - CASH AND INVESTMENTS AS OF DECEMBER 31, 2023 WERE $337.7 MILLION   * IGM BIOSCIENCES INC - EXPECTS FULL YEAR 2024 GAAP OPERATING EXPENSES OF $210 MILLION TO $220 MILLION   * IGM BIOSCIENCES - SEES TO END 2024 WITH A BALANCE OF ABOUT $180 MILLION IN CASH AND INVESTMENTS   * IGM BIOSCIENCES - SEES CASH BALANCE TO ENABLE IT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q2 OF 2026Source text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","IGM":"iShares Expanded Tech Sector ETF","IGMS":"IGM Biosciences"},"translate_title":"简介-IGM Biosciences公布第四季度及2023年全年财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IGM":1,"IGMS":1},"content_text":"March 7 (Reuters) - IGM Biosciences Inc   :   * IGM BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE   * IGM BIOSCIENCES INC - CASH AND INVESTMENTS AS OF DECEMBER 31, 2023 WERE $337.7 MILLION   * IGM BIOSCIENCES INC - EXPECTS FULL YEAR 2024 GAAP OPERATING EXPENSES OF $210 MILLION TO $220 MILLION   * IGM BIOSCIENCES - SEES TO END 2024 WITH A BALANCE OF ABOUT $180 MILLION IN CASH AND INVESTMENTS   * IGM BIOSCIENCES - SEES CASH BALANCE TO ENABLE IT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q2 OF 2026Source text for Eikon:    Further company coverage:","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2417203748"}